The UK healthcare sector is mourning one of the most eminent of its figures in the last few decades – Professor Sir Mike Rawlins – who has passed away at the age of 81.
The FDA's interactions with Biogen in the build-up to last year's controversial approval of Alzheimer's disease therapy Aduhelm have been described as "inappropriate" and "atypical" in a co
The FDA has given a green light to Roche's CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed or refractory follicular lymphoma, following the lead of the European Commission
One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<
Regulators in the US and EU have started a review of Pfizer's S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions e
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.